FDA Fast-Tracks Potential New Therapy for Dry AMD

In promising news for the vision community, the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RPESC-RPE-4W transplantation, a novel cell therapy developed by Luxa Biotechnology LLC. This designation aims to accelerate the development and review process for this potential treatment for dry age-related macular degeneration (AMD).

While this specific therapy targets dry AMD, a condition distinct from inherited retinal diseases (IRDs), the IRD community often watches advancements in AMD research closely. Both AMD and IRDs are leading causes of irreversible vision loss and share commonalities in the progressive loss of photoreceptors and associated genetic risk factors. Progress in one area of retinal disease research can sometimes inform or inspire new approaches in others, offering a broader sense of hope for future treatments across the spectrum of retinal degenerations.

What is RPESC-RPE-4W?

RPESC-RPE-4W is a cell product derived from adult retinal pigment epithelial stem cells (RPESC). These stem cells are designed to generate retinal pigmented epithelium (RPE) cell progeny (RPESC-RPE). The transplantation of these progenitor-stage RPESC-RPE cells, after four weeks of differentiation, is intended to replace the native RPE cells that are lost during the progression of AMD.

Understanding RMAT Designation

The Regenerative Medicine Advanced Therapy (RMAT) designation was established under the 21st Century Cures Act to expedite the development and review of promising regenerative medicine therapies. To qualify for RMAT, a therapy must be a regenerative medicine therapy, intended to treat a serious or life-threatening condition, and show preliminary clinical evidence suggesting its potential to address an unmet medical need.

This designation provides several benefits, including increased interaction with the FDA to guide and accelerate clinical development, potential for accelerated approval, and priority review of the product's biologics license application (BLA). Luxa Biotechnology's CEO, Keith Dionne, PhD, stated that the RMAT designation was granted following the FDA's review of